Verrica PharmaceuticalsVRCA
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 33 institutions reported holding Verrica Pharmaceuticals Inc. (VRCA) in their 13F filings, up 28 from Q2 2025. 7 opened new positions and 5 sold out. The largest holders were Caligan Partners LP ($4.0M), Armistice Capital, LLC ($2.8M) and Boothbay Fund Management, LLC ($1.2M). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Verrica Pharmaceuticals Inc.
- CUSIP
- 92511W207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $1.3M |
| Exits | 5 | $103K |
All 13F filers, Q2 2025 → Q3 2025: 392,647 shares bought and 468,313 shares sold, net −75,665 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 33 holders
| Caligan Partners LP | 0.55% | No change | 923,910 | $4.0M |
| Armistice Capital, LLC | 0.09% | Reduce -28.0% | 639,193 | $2.8M |
| Boothbay Fund Management, LLC | 0.03% | New | 280,734 | $1.2M |
| Vanguard Group Inc. | 0.00% | Add +3.9% | 225,210 | $971K |
| Millennium Management | 0.00% | Reduce -20.6% | 71,990 | $310K |
| Geode Capital Management, LLC | 0.00% | Add +4.7% | 67,659 | $292K |
| Sovran Advisors, LLC | 0.02% | Reduce -1.6% | 73,805 | $261K |
| UBS Group AG | 0.00% | Add +472.4% | 41,632 | $179K |
| Renaissance Technologies | 0.00% | Add +234.8% | 29,191 | $126K |
| Mariner, LLC | 0.00% | Reduce -7.5% | 24,550 | $106K |
| Morgan Stanley | 0.00% | Add +725.7% | 21,688 | $93K |
| State Street Corp. | 0.00% | Add +124.2% | 20,581 | $89K |
| Northern Trust Corp. | 0.00% | Reduce -3.4% | 20,031 | $86K |
| Bridgeway Capital Management, LLC | 0.00% | New | 12,000 | $52K |
| BlackRock, Inc. | 0.00% | Add +8.9% | 6,148 | $26K |
| FMR LLC | 0.00% | Reduce -14.7% | 3,337 | $14K |
| Citigroup Inc. | 0.00% | Add +506.6% | 2,065 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -42.6% | 1,543 | $7K |
| Capital Analysts, LLC | 0.00% | Reduce -29.6% | 1,500 | $6K |
| Royal Bank of Canada | 0.00% | Add +139.3% | 1,209 | $5K |
| Salomon & Ludwin, LLC | 0.00% | No change | 290 | $1K |
| New England Capital Financial Advisors LLC | 0.00% | New | 200 | $862 |
| Nisa Investment Advisors, LLC | 0.00% | Reduce -0.8% | 142 | $612 |
| BNP Paribas Financial Markets | 0.00% | Reduce -10.1% | 124 | $534 |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -1.1% | 102 | $439 |
| Bank of America Corp. | 0.00% | Reduce -82.6% | 72 | $310 |
| Optiver Holding B.V. | 0.00% | New | 31 | $134 |
| Arax Advisory Partners | 0.00% | New | 9 | $38 |
| Group One Trading LLC | 0.00% | Add +25.0% | 3 | $13 |
| MAI Capital Management | 0.00% | New | 2 | $9 |
| Barclays PLC | 0.00% | Reduce -37.5% | 1 | $4 |
| Cwm, LLC | 0.00% | New | 28 | $0 |
| Covestor Ltd | 0.00% | Reduce -0.9% | 54 | $0 |
"% of holder's portfolio" is VRCA's weight in each manager's 13F, not the share of Verrica Pharmaceuticals Inc. the manager owns.